Handelsbanken Fonder AB Acquires Shares of 165,000 Structure Therapeutics Inc. (NASDAQ:GPCR)

Handelsbanken Fonder AB bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 165,000 shares of the company's stock, valued at approximately $4,475,000. Handelsbanken Fonder AB owned approximately 0.29% of Structure Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company's stock valued at $341,015,000 after purchasing an additional 221,851 shares during the last quarter. FMR LLC lifted its stake in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company's stock valued at $268,977,000 after buying an additional 383,635 shares during the period. Janus Henderson Group PLC boosted its position in Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock worth $173,623,000 after acquiring an additional 602,609 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company's stock worth $54,348,000 after acquiring an additional 820,589 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock valued at $50,474,000 after acquiring an additional 590,000 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on GPCR shares. Stifel Nicolaus began coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Price Performance

NASDAQ GPCR traded up $2.94 during trading hours on Thursday, hitting $22.82. The company had a trading volume of 1,591,478 shares, compared to its average volume of 797,217. Structure Therapeutics Inc. has a fifty-two week low of $19.61 and a fifty-two week high of $62.74. The firm's 50 day moving average is $26.80 and its 200 day moving average is $33.74. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -30.84 and a beta of -2.75.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.